<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279979</url>
  </required_header>
  <id_info>
    <org_study_id>Thoratec HeartMate PHP™ CS</org_study_id>
    <nct_id>NCT02279979</nct_id>
  </id_info>
  <brief_title>Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial</brief_title>
  <official_title>Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thoratec Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess reasonable safety and performance of the&#xD;
      HeartMate PHP to provide hemodynamic support for up to 72 hours in patients with cardiogenic&#xD;
      shock requiring stabilization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HeartMate PHP is a catheter-based axial flow pump designed to provide partial left&#xD;
      ventricular circulatory support. This prospective, nonrandomized, controlled, single-arm,&#xD;
      multi-center, open-label trial will evaluate the safety and performance of the device in&#xD;
      patients with cardiogenic shock.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical stabilization defined as improvement of Cardiac Index to &gt; 2.2 L/min/m2</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>An assessment of major adverse events</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will be treated with the HeartMate PHP device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartMate PHP</intervention_name>
    <description>The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is indicated for left ventricular support according to current medical&#xD;
             guidelines (&quot;current medical guidelines&quot; applies only to patients enrolled in Germany)&#xD;
&#xD;
          2. Patient has a cardiac index of &lt; 2.2 L/min/m2 and is being treated with at least one&#xD;
             moderate dose inotrope or at least one moderate dose of vasopressor (e.g., milrinone&#xD;
             ≥0.3 mcg/kg/min, dopamine &gt; 5 mcg/kg/min, dobutamine &gt; 5 mcg/kg/min) AND:&#xD;
&#xD;
               -  PCWP &gt; 18 mmHg, AND&#xD;
&#xD;
               -  Systolic blood pressure &lt; 100 mmHg, AND&#xD;
&#xD;
               -  Decreased organ perfusion as evidenced by urine output of 50 mL/hr OR increased&#xD;
                  creatinine of 0.3 mg/dl from baseline obtained within 2 weeks, OR cool&#xD;
                  extremities&#xD;
&#xD;
          3. Written, signed, and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is &gt;85 years of age&#xD;
&#xD;
          2. Right ventricular failure requiring mechanical circulatory support&#xD;
&#xD;
          3. ST elevation myocardial infarction (STEMI) within 30 days of procedure&#xD;
&#xD;
          4. Cardiac arrest within 7 days of procedure requiring CPR&#xD;
&#xD;
          5. Current treatment with mechanical circulatory device such as IABP, ECMO, centrifugal&#xD;
             pump, etc.&#xD;
&#xD;
          6. Documented acute myocarditis&#xD;
&#xD;
          7. Active major cardiac rhythm disturbances (e.g., ventricular tachycardia, ventricular&#xD;
             fibrillation).&#xD;
&#xD;
          8. Hypertrophic disease or any left ventricular outflow tract obstruction&#xD;
&#xD;
          9. Active sepsis defined as bacteremia, fever ≥ 101.5 degrees F&#xD;
&#xD;
         10. Mural thrombus in the left ventricle&#xD;
&#xD;
         11. History of aortic valve replacement&#xD;
&#xD;
         12. End-stage renal disease requiring dialysis&#xD;
&#xD;
         13. Documented presence of aortic stenosis (orifice area of 1.5 cm2 or less)&#xD;
&#xD;
         14. Moderate to severe aortic insufficiency (echocardiographic assessment of aortic&#xD;
             insufficiency graded as 2 or higher)&#xD;
&#xD;
         15. Platelet count &lt; 100,000&#xD;
&#xD;
         16. Allergy or Intolerance to heparin, aspirin, clopidogrel, ionic and nonionic contrast&#xD;
             media, or any other potentially required anticoagulants or antiplatelet therapy drugs&#xD;
&#xD;
         17. Known coagulopathies&#xD;
&#xD;
         18. Presence of risk factors for severe liver and/or renal dysfunction&#xD;
&#xD;
         19. Stroke within 90 days of enrollment&#xD;
&#xD;
         20. Significant peripheral vascular disease&#xD;
&#xD;
         21. History of heparin induced thrombocytopenia&#xD;
&#xD;
         22. Patient is pregnant or planning to become pregnant during the study period&#xD;
&#xD;
         23. Patient is breastfeeding.&#xD;
&#xD;
         24. Any active disease (e.g., active cancer) which could affect the patient's&#xD;
             participation in the study, or if life expectancy is less than 1 year.&#xD;
&#xD;
         25. Any active disease in which the investigator determines would make the patient an&#xD;
             inappropriate candidate for the study.&#xD;
&#xD;
         26. Participation in another clinical study of an investigational drug or device that has&#xD;
             not met its primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poornima Sood, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Thoratec LLC, St. Jude Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>130 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000-CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PHP</keyword>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Percutaneous</keyword>
  <keyword>Ventricular Assist</keyword>
  <keyword>Heart Pump</keyword>
  <keyword>Catheter</keyword>
  <keyword>Thoratec Corporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

